III-01 Angela Äbelö
Population concentration-QT-modelling of CHF6001 following dry powder inhalation in healthy volunteers.
Thursday 09:55-11:30 |
III-02 Nada Abla Geiser
Development of PBPK drug models to support antimalarial combination strategy
Thursday 09:55-11:30 |
III-03 Amais Ahmad
Evaluation of Prediction Performance of In Silico PBPK models of oral drug absorption
Thursday 09:55-11:30 |
III-04 Jae Eun Ahn
Pharmacokinetic/Pharmacodynamic effects of PF-06648671, a novel gamma secretase modulator following single and multiple dose administration in healthy volunteers
Thursday 09:55-11:30 |
III-05 Yasunori Aoki
Second order Taylor expansion of likelihood-based models for fast covariate and random effect model building
Thursday 09:55-11:30 |
III-06 Usman Arshad
Development of visual predictive checks accounting for multimodal parameter distributions in mixture models
Thursday 09:55-11:30 |
III-07 Muhammad Waqar Ashraf
A semi-PBPK model to describe the mechanism based drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers.
Thursday 09:55-11:30 |
III-08 Magnus Ĺstrand
Longitudinal pharmacometric modelling of serum potassium lowering effect of sodium zirconium cyclosilicate in patients with hyperkalemia
Thursday 09:55-11:30 |
III-09 Linda Aulin
Quantitative modelling of procalcitonin as a treatment response biomarker in sepsis
Thursday 09:55-11:30 |
III-10 Geraldine Celliere
Development of guidelines to efficiently choose and diagnose target-mediated drug disposition models
Thursday 09:55-11:30 |
III-11 Vanessa Baier
Developing a physiology-based model of bile acid metabolism in men
Thursday 09:55-11:30 |
III-12 Pavel Balazki
A Physiologically-based Quantitative Systems Pharmacology model of the incretin hormones GLP-1 and GIP
Thursday 09:55-11:30 |
III-13 Belén Pérez Solans
Mechanistic model of the myeloablative effects of treosulfan and busulfan in pediatric patients undergoing bone marrow transplant
Thursday 09:55-11:30 |
III-14 Irina Baltcheva
Model-based dose selection for the Phase 2b study of ianalumab in primary Sjögren's Syndrome
Thursday 09:55-11:30 |
III-15 Guillaume Baneyx
Target-mediated drug disposition modeling of lacnotuzumab in healthy volunteers and patients with advanced malignancies and triple negative breast cancer.
Thursday 09:55-11:30 |
III-16 Catalina Barceló
Modelling waist-hip ratio increase in HIV-infected individuals starting antiretroviral therapy
Thursday 09:55-11:30 |
III-17 Christian Bartels
ggPMX: a toolbox to easily generate a comprehensive set of model diagnostic plots for population models
Thursday 09:55-11:30 |
III-18 Roberta Bartolucci
A PBPK model for the study of Azathioprine pharmacokinetics in rats and prediction in humans
Thursday 09:55-11:30 |
III-19 Carla Bastida Fernández
PK/PD of the individual components of composite indexes variables used for disease activity assessment in rheumatoid arthritis patients on tocilizumab treatment.
Thursday 09:55-11:30 |
III-20 Ryan Beechinor
A population pharmacokinetic study of high dose methotrexate treatment in infants with acute lymphoblastic leukemia: The importance of modeling inter-occasion variability across treatment cycles
Thursday 09:55-11:30 |
III-21 Amina Bensalem
Concentration-effect relationships of therapeutic monoclonal antibody rituximab in rheumatoid arthritis.
Thursday 09:55-11:30 |
III-22 Agathe Béranger
Piperacillin dosing regimen optimization in critically ill children according to different creatinine clearances
Thursday 09:55-11:30 |
III-23 Agnieszka Bienert
Pharmacokinetics of dexmedetomidine in elderly patients undergoing sedation after abdominal aortic surgery.
Thursday 09:55-11:30 |
III-24 Robert Bies
Pharmacokinetic-pharmacodynamic modelling of MK-2048 in ex vivo cervical tissue
Thursday 09:55-11:30 |
III-25 Henrik Bjugĺrd Nyberg
A pediatric population pharmacokinetic model for ethionamide in South African children treated for drug-susceptible or drug-resistant tuberculosis.
Thursday 09:55-11:30 |
III-26 Alessandro Boianelli
A quantitative systems pharmacology model for understanding the role of dietary fructose metabolism in NAFLD
Thursday 09:55-11:30 |
III-27 Charlotte Bon
Capacity limits of ASGPR mediated liver targeting
Thursday 09:55-11:30 |
III-28 Rolien Bosch
A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist.
Thursday 09:55-11:30 |
III-29 Ari Brekkan Viggosson
Characterization of anti-drug antibodies using a bivariate mixed hidden Markov model
Thursday 09:55-11:30 |
III-30 Philippine Eloy
Genetics of nevirapine and anti-tuberculosis drugs pharmacokinetics interaction in HIV-tuberculosis co-infected patients in Mozambique
Thursday 09:55-11:30 |
III-31 Hannah Britz
Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine
Thursday 09:55-11:30 |
III-32 Astrid Broeker
An integrated pharmacometric dialysis model to evaluate the pharmacokinetic impact of renal replacement therapy
Thursday 09:55-11:30 |
III-33 Jantine Brussee
Dose Individualization of CYP3A Substrates in Children: Characterization of Maturation of Intestinal and Hepatic CYP3A Activity in Children to Predict First-pass and Systemic CYP3A-mediated Metabolism
Thursday 09:55-11:30 |
III-34 Thierry Buclin
Closed-loop control for propofol administration during anesthesia based on real-time concentration measurement: a simulation study
Thursday 09:55-11:30 |
III-35 Wonkyung Byon
Apixaban for treatment of venous thromboembolism (VTEtx): Use of Model-Based Meta-Analysis (MBMA) to support Phase 3 dose selection and beyond
Thursday 09:55-11:30 |
III-36 Tim Cardilin
Modeling of radiation therapy and radiosensitizing agents in tumor xenografts
Thursday 09:55-11:30 |
III-37 Evelina Cardoso
Population pharmacokinetic analysis of erlotinib in cancer patients affected by NSCLC
Thursday 09:55-11:30 |
III-38 Marc Cerou
HAM-D score analysis of patients under placebo with major depressive disorder using item response theory
Thursday 09:55-11:30 |
III-39 Blesson Chacko
Covariate effects on competing events: a simulation study comparing approaches
Thursday 09:55-11:30 |
III-40 Dong Woo Chae
Predictive Modeling of PCA Effect on Postoperative Pain Management
Thursday 09:55-11:30 |
III-41 Anne Chain
Extension of population pharmacokinetic analysis of pembrolizumab to paediatric patients patients with classical Hodgkin lymphoma
Thursday 09:55-11:30 |
III-42 Pascal Chanu
Pediatric plans optimization of C.E.R.A. (Continuous Erythropoietin Receptor Activator): clinical evidence obtained through a model-based integration of multisource data
Thursday 09:55-11:30 |
III-43 Estelle Chasseloup
Generation and Application of Avatars (Digital Twins) in Pharmacometric Modelling
Thursday 09:55-11:30 |
III-44 Jonathan Chauvin
COSSAC (COnditional Sampling use for Stepwise Approach based on Correlation tests) method for covariate search
Thursday 09:55-11:30 |
III-45 Chee Ng
Novel Multilevel Parallel Expectation Maximization (MPEM) Estimation Methods for Population Quantitative Pharmacology Analysis
Thursday 09:55-11:30 |
III-46 Wenjun Chen
Modeling the antitumor efficacy and pharmacokinetic/pharmacodynamic interaction between docetaxel and cabozantinib in human prostate cancer xenograft mouse models
Thursday 09:55-11:30 |
III-47 Mohammed Cherkaoui Rbati
A Liver Model for Chemoprotection Against Malaria
Thursday 09:55-11:30 |
III-48 Manoranjenni Chetty
Antidepressants, anxiolytics and statins: prediction of exposure changes due to aging
Thursday 09:55-11:30 |
III-49 S. Y. Amy Cheung
Challenges and opportunities in the development of medical therapies for paediatric populations and the role of extrapolation
Thursday 09:55-11:30 |
III-50 Maxwell Chirehwa
Correlates of tuberculosis treatment outcomes: application of regression trees and pharmacodynamic modelling techniques
Thursday 09:55-11:30 |
III-51 Jason Chittenden
PMDatR: A Pharmacometric Data Manipulation Package for R
Thursday 09:55-11:30 |
III-52 Young-Kyung Choi
Population pharmacokinetics of cycloserine in patients with multidrug-resistant tuberculosis
Thursday 09:55-11:30 |
III-53 Francois Combes
Modeling and Simulation Approach of Everolimus PK/PD Toward Completing a Pediatric Development
Thursday 09:55-11:30 |
III-54 Valerie Cosson
Population PKPD modeling of RO7046015 (PRX002/RG7935), an Anti--Synuclein Monoclonal Antibody for the treatment of Parkinson’s Disease
Thursday 09:55-11:30 |
III-55 Perrine Courlet
Comparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort
Thursday 09:55-11:30 |
III-56 Vincent Croixmarie
Use of a multivariate distribution to simulate severe renal impaired patients
Thursday 09:55-11:30 |
III-57 Ailing Cui
Quantitative Predictive Models for the Degree of Disability After Acute Ischemic Stroke
Thursday 09:55-11:30 |
III-59 André Dallmann
Characterization of paracetamol hepatotoxicity during pregnancy through physiologically-based pharmacokinetic modeling
Thursday 09:55-11:30 |
III-60 Daniel Kaschek
An Integrated R-Based Framework for Model Development in Health Economics
Thursday 09:55-11:30 |
III-61 Kim Dao
Evaluation of exposure to vancomycin in neonates under existing dosing regimens using a population pharmacokinetic approach
Thursday 09:55-11:30 |
III-62 Olivier David
A PKPD model describing the amyloid precursor protein (APP) derived peptides in subjects receiving CNP520, a BACE-1 inhibitor.
Thursday 09:55-11:30 |
III-63 Nico de Jager
Population pharmacokinetic modelling of factor VIII levels during perioperative dosing of Haemate® P (Humate P) in patients diagnosed with von Willebrands Disease.
Thursday 09:55-11:30 |
III-64 Giuseppe De Nicolao
Analysis of muscular biopsy distributional data in Duchenne Muscular Dystrophy treatment: a population approach
Thursday 09:55-11:30 |
III-65 Mailys De Sousa Mendes
Mechanistic modelling of in-vitro bidirectional permeability studies and in vivo absorption of metoprolol
Thursday 09:55-11:30 |
III-66 Elien De Thaye
In vitro data supporting circulating CCCK18 as potential pharmacodynamic biomarker in ovarian cancer
Thursday 09:55-11:30 |
III-67 Aurelia de Vries Schultink
Therapeutic drug monitoring of endoxifen in ER-positive breast cancer patients: comparing data from clinical practice to model-based predictions.
Thursday 09:55-11:30 |
III-68 Neel Deferm
A Mechanistic Cellular Disposition Model of Bile Acid Handling in Sandwich-Cultured Human Hepatocytes
Thursday 09:55-11:30 |
III-69 Oleg Demin
Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology
Thursday 09:55-11:30 |
III-70 Oleg Demin Jr
Quantitative Systems Pharmacology Modeling of CAR-T Therapy and T Cell Engaging Bispecific Antibodies: B-cell Acute Lymphoblastic Leukemia Case Study
Thursday 09:55-11:30 |
III-71 Aris Dokoumetzidis
Population pharmacokinetics of teicoplanin in preterm and term neonates with late-onset sepsis
Thursday 09:55-11:30 |
III-72 Artem Dolgun
A functional, integrative R environment workflow for the development and use of quantitative systems pharmacology models
Thursday 09:55-11:30 |
III-73 Anne-Gaelle Dosne
Optimizing Biomarker-Based Dosing Algorithm for Erdafitinib through PK-PD Modeling and Simulations
Thursday 09:55-11:30 |
III-74 Erwin Dreesen
Development of a population pharmacokinetic and pharmacodynamic model to describe the effect of infliximab induction therapy on mucosal healing in patients with ulcerative colitis
Thursday 09:55-11:30 |
III-75 Vincent Dubois
Comparative attributes of a semimechanistic and an empirical population PK model for durvalumab, a fully human anti-PD-L1 monoclonal antibody
Thursday 09:55-11:30 |
III-76 Miro Eigenmann
Dynamic in vitro PKPD assessment to improve pharmacological response profiling of T-cell bispecifics
Thursday 09:55-11:30 |
III-77 Salvatore D'Agate
Development of a drug-disease model describing individual IPSS trajectories in BPH patients: Implication of disease progression and covariate factors on long term treatment response
Thursday 09:55-11:30 |
